Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00358293
Recruitment Status : Completed
First Posted : July 31, 2006
Last Update Posted : January 21, 2009
Sponsor:
Information provided by:
Teva GTC

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Primary Completion Date : No date given
Actual Study Completion Date : February 2007